First patients to test new cancer drug in hopes of controlling advanced tumors
NCT ID NCT06332755
Summary
This is the first study in people to test a new drug called LB-LR1109. The main goal is to find a safe and tolerable dose for patients with advanced or metastatic solid tumors, including lung, head and neck, kidney, bladder cancers, and melanoma. The study will test the drug alone and, for lung cancer patients, in combination with an existing immunotherapy drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.